Lexeo Therapeutics Business Summary

Lexeo Therapeutics, Inc. (LXEO) is a clinical-stage genetic medicine company that operates primarily through a research and development business model, generating revenue through strategic collaborations, licensing agreements, and milestone payments rather than commercial product sales. The company’s operations are concentrated in a single business segment focused on the development of adeno-associated virus (AAV)-based gene therapies. Its pipeline is bifurcated into two high-growth therapeutic areas: genetically defined cardiovascular diseases, such as Friedreich’s ataxia cardiomyopathy (LX2006) and PKP2-associated arrhythmogenic cardiomyopathy (LX2020), and APOE4-associated Alzheimer’s disease (LX1001). Lexeo competes directly with precision medicine firms such as Tenaya Therapeutics, Sarepta Therapeutics, Taysha Gene Therapies, and Solid Biosciences, positioning itself as a specialized leader in the intersection of cardiac and neurodegenerative genetic interventions. Lexeo was founded in 2018 by Dr. Ronald Crystal, a pioneer in human gene therapy and Chairman of Genetic Medicine at Weill Cornell Medicine. The leadership team is led by CEO R. Nolan Townsend, who previously served as President of Pfizer Rare Disease for North America and International markets. In early 2026, the company strengthened its executive suite by appointing Dr. Narinder Bhalla, formerly a Senior Vice President at Bristol Myers Squibb, as Chief Medical Officer, and promoting Dr. José Manuel Otero to Chief Operating Officer from his previous role as Chief Technical Officer. The company is supported by a sophisticated investor base and board, including institutional backers such as Longitude Capital, Adage Capital Management, RA Capital Management, and Sarepta Therapeutics, with a board of directors chaired by Dr. Steven Altschuler, the former CEO of the Children’s Hospital of Philadelphia.